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Abstract The deregulation ofWnt signaling is observed in var-
ious cancers, including gliomas, and might be related to the
methylation of the genes encoding antagonists of this signaling
pathway. The aim of the study was to assess the methylation
status of the promoter regions of six Wnt negative regulators
and to determine their prognostic value in clinical samples of
gliomas of different grades. The methylation of SFRP1,
SFRP2, PPP2R2B, DKK1, SOX17, and DACH1 was analyzed
in 64 glioma samples using methylation-specific polymerase
chain reaction (MSP). The results were analyzed in correlation
with clinicopathological data. Promoter methylation in at least
one of the analyzed geneswas found in 81.3%of the tumors. All
benign tumors [grade I according to the World Health
Organization (WHO) classification] lacked the methylation of
the studied genes, whereas grade II, III, and IV tumors were, in
most cases, methylation-positive. The methylation index corre-
lated with the patient’s age. The most frequently methylated
genes were SFRP1 and SFRP2 (73.4 % and 46.9 %, respective-
ly), followed by SOX17 (20.3 %) and PPP2R2B (10.9 %);
DKK1 and DACH1 were basically unmethylated (1.6 %).
SFRP1methylation negatively correlated with patients’ survival
time, and was significantly more frequent in older patients and
those with higher grade tumors. Overall, the results of this study
indicate that aberrant promoter methylation of Wnt pathway
antagonists is common in gliomas, which may be the possible
cause of up-regulation of this signaling pathway often observed
in these tumors. Moreover, SFRP1 promoter methylation can be
regarded as a potential indicator of glioma patients’ survival.
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Introduction
Gliomas are the most common primary brain tumors in adults,
with a wide spectrum of different tumor types. According to
the World Health Organization (WHO), they can be divided
into low-grade gliomas (WHO grades I and II) and high-grade
gliomas (WHO grades III and IV). The most aggressive form
of glioma, glioblastoma multiforme (GBM), is basically in-
curable and the most lethal among solid tumors (Schiefer et al.
2014). In adult patients, it is a rule that low-grade gliomas tend
to progress to higher grade malignancies (Ostrom et al. 2014).
Unraveling molecular routes leading to glioma development
and searching for new diagnostic, prognostic, or predictive
biomarkers remains crucial for better diagnosis and more ef-
ficient management of these tumors.
In recent years, epigenetic biomarkers based on the analy-
sis of the DNAmethylation profile have proven to be useful in
the detection of and prognostication in various cancer types
(Paluszczak and Baer-Dubowska 2006; Majchrzak-Celińska
et al. 2013, 2015a, b; Ellinger et al. 2015). In this regard, our
previous study showed that DNA methylation of a panel of
selected genes can serve as a tool for the prediction of glioma
aggressiveness. Moreover, among the individual genes,
RUNX3, encoding a negative regulator of the Wnt/β-catenin
signaling pathway, was found to be the most promising can-
didate for a new biomarker (Majchrzak-Celińska et al. 2015a).
The activation of Wnt/β-catenin signaling promotes a large
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spectrum of cellular processes, such as proliferation, differen-
tiation, cell adhesion, and migration (Rao and Kühl 2010). In
the absence of Wnt ligands, Axin/APC/GSK3β/β-catenin to-
gether form a multiprotein destruction complex in which β-
catenin is phosphorylated by GSK3β and subsequently de-
graded by the proteasome. In the nucleus, in the absence of
β-catenin, TCF/LEF proteins actively repress target genes
through the recruitment of transcriptional co-repressors such
as C-terminal-binding protein (CtBP) and Groucho (Gro)
(Paul et al. 2013; Zhang et al. 2012). When Wnt ligands bind
to Frizzled receptors, the transmembrane Dishevelled protein
is activated, which inhibits the activity of GSK3β, thereby
blocking the degradation of β-catenin. The accumulation of
β-catenin in the cytoplasm leads to its translocation to the
nucleus, where it binds to the TCF/LEF family of transcription
factors and stimulates the transcription of multiple target
genes (Paul et al. 2013; Zhang et al. 2012) (Fig. 1).
The imbalance in the structural and signaling properties
of β-catenin often results in deregulated cellular growth
related to cancer and metastasis (Kaur et al. 2013;
Paluszczak et al. 2014, 2015; Surana et al. 2014). The
up-regulation of Wnt signaling was also observed in glio-
mas and it was suggested that it might be related not only
to enhanced cancer cell proliferation, but also to radio-
and chemoresistance (Schiefer et al. 2014). Multiple ways
of deregulation of the Wnt/β-catenin pathway were pro-
posed and several aberrantly expressed molecules were
indicated as potential biomarkers. For instance, increased
β-catenin expression has been observed in astrocytic tu-
mors, which correlated with poor prognosis and short sur-
vival of GBM patients (Liu et al. 2011; Rossi et al. 2011).
Also, the inactivation of key components of the β-catenin
degradation complex, such as Axin, was found to be com-
mon in brain tumors and, importantly, the levels of Axin
correlated negatively with the grade of astrocytoma (Zhang
et al. 2009). Recent studies supporting a role for a
deregulated Wnt/ β-catenin pathway in malignant glioma
also showed that Wnt pathway antagonists such as WIF1
and a family of secreted Frizzled-related proteins,
dickkopf, and naked are epigenetically inactivated as a
result of their promoters’ hypermethylation (Lambiv et al.
2011; Götze et al. 2010). However, little is still known
about the role of the Wnt pathway in the malignant be-
havior of human glioma. Moreover, most of the studies on
the epigenetic inactivation of Wnt/β-catenin pathway an-
tagonists were performed using cell line models or tested
only a small number of genes (Schiefer et al. 2014; Kim
et al. 2013).
The aim of the present study was to assess the frequency of
the promoter methylation of genes encoding two members of
secreted Frizzled-related protein family (SFRP1, SFRP2), one
dickkopf family member (DKK1), and three others, namely
PPP2R2B, SOX17, and DACH1, all acting as Wnt pathway
negative regulators. The genes were selected on the basis of
their ability to inhibit different levels of the Wnt pathway
(Fig. 1) and their potential role in glioma carcinogenesis. In
order to establish the diagnostic or prognostic potential of the
studied genes, the correlation with important clinicopatholog-
ical data such as tumor grade according toWHO classification
criteria, patients’ age, gender, and survival time was
evaluated.
We found the hypermethylation of SFRP1 and SFRP2 gene
promoters to be the most frequent. Moreover, correlation of
SFRP1 methylation with tumor grade and patients’ survival




The study group consisted of 64 patients with glial tumors
who were primarily treated surgically at the Department and
Clinic of Neurosurgery and Neurotraumatology of Poznan
University of Medical Sciences between 2010 and 2013.
The histological types of the tumors as well as tumor grades
(according to the 2007 WHO classification criteria) were an-
alyzed in the Laboratory of Neuropathology. Twenty-six pa-
tients were diagnosed with WHO grade IV glioma, twenty-
three with grade III, nine with grade II, and four with grade I
tumors. Two patients were not classified according to the
WHO grading scale. Women comprised 43.75 % (28/64)
and men 56.25 % (36/64) of all patients, and the average
patient age was 52 years (median 56 years), ranging from 16
to 83 years. The more detailed characteristics of the studied
group is presented in Table 1. Directly after resection, tumor
samples were frozen and stored at −80 °C.
The follow-up observation in most cases covered at least
2 years following tumor resection and the information about
patients’ overall survival time was available for more than half
of the patients (34/64). All the patients gave informed consent
for the analyses to be undertaken and the study protocol was
approved by the Clinical Research Ethics Committee (approv-
al no. 505/12).
Isolation of DNA from tumor tissue
DNA from tumor samples was isolated using the
GeneMATRIX Tissue DNA Purification Kit (EURx,
Gdańsk, Poland), following the manufacturer’s instructions.
DNA concentration and purity were measured using a
NanoDrop Spectrophotometer and then the DNA was stored
at −20 °C for further analysis.
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Methylation-specific polymerase chain reaction (MSP)
Bisulfite modification of 500 ng DNA was performed using
the EZ DNAMethylation Kit (Zymo Research, Irvine, USA).
SFRP1, SFRP2, PPP2R2B, DKK1, SOX17, and DACH1 pro-
moter methylation was assessed with methylation-specific po-
lymerase chain reaction (MSP). Primers were obtained from
Oligo.pl (Warsaw, Poland). Primer sequences along with their
corresponding annealing temperature are presented in Table 2.
All MSP reactions were performed in a MyCycler Thermal
Cycler with Gradient (Bio-Rad, Hercules, USA) or a T100
Thermal Cycler with Gradient (Bio-Rad, Hercules, USA),
using HOT FIREPol DNA Polymerase (Solis BioDyne,
Tartu, Estonia). The reaction protocol was as follows: poly-
merase activation at 95 °C for 15 min, 40 cycles of 95 °C for
30 s, annealing at the appropriate temperature for 30 s and
72 °C for 30 s, then final elongation at 72 °C for 5 min and
hold at 4 °C. MSP products were separated by electrophoresis
on 2 % agarose gels and visualized under UV light illumina-
tion after staining with SimplySafe (EURx, Gdańsk, Poland).
Representative electropherograms of SFRP1 and SFRP2MSP
reactions are presented in Fig. 2b. Completely methylated
DNA (CpG Methylated HeLa Genomic DNA, New England
Biolabs, Ipswich, USA), DNA extracted from white blood
cells of a healthy blood donor (WBC), and water served as
positive, negative, and blank controls in MSP reactions, re-
spectively. Non-cancerous brain tissue from a patient with
brain hematoma and Human Astrocyte Genomic DNA
(ScienCell Research Laboratories, Carlsbad, USA) served as
additional controls for methylation status in non-cancerous
brain tissue.
Statistical analysis
The correlation between clinicopathological features and gene
methylation was assessed using CSS Statistica, version 10.
The Chi-square test was used to determine the correlations
between detected methylation and patients’ age, gender, and
tumor WHO grade, and Spearman’s rank correlation coeffi-
cient was applied to measure the dependence between the
methylation index (MI) and patients’ age or tumor WHO
grade, while the Mann–Whitney U-test verified if promoter
methylation correlates with patients’ survival time.
Results
Methylation in at least one of the six analyzed genes occurred
in 81.3 % of the tumors, while 46.9 % of the cases showed
methylation in at least two genes. None of the genes were
methylated in DNA derived from either normal human astro-
cytes or non-cancerous brain tissue. This indicates that the
observed changes are cancer-specific. All benign, grade I tu-
mors had no methylated genes detected, whereas grade II, III,
Fig. 1 The role of proteins encoded by genes analyzed in this study in the
inhibition of the Wnt signaling. The secreted Frizzled-related proteins
sFRP1 and sFRP2 are receptors for secreted Wnt proteins, as well as
other ligands. The interaction between sFRPs and Wnt proteins
prevents the latter from binding the Frizzled receptors (Pannone et al.
2010). The Wnt inhibitor Dkk1 encoded by the DKK1 gene acts also at
the cell membrane level through binding the Frizzled co-receptor LRP,
causing its internalization (Zhou et al. 2010). The protein encoded by the
PPP2R2B gene is a part of the β-catenin degrading complex (Tan et al.
2010). The last two proteins encoded by the SOX17 and DACH1 genes
act as transcription factors inhibiting the expression of the Wnt pathway
target genes. SOX17 also degrades β-catenin independently of the
degrading complex (Sinner et al. 2007), while DACH1 inhibits the
expression of the Frizzled receptor protein (Wu et al. 2003; Yan et al.
2013)
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and IV tumors were, in most cases, methylation-positive.
However, the average MI, defined as the number of methyl-
ated genes divided by the number of all genes analyzed in the
panel (Chen et al. 2011), did not differ significantly between
groups of patients with different WHO grades. Neither did it
for patients grouped according to their gender. Nevertheless,
the MI of individual patients correlated with their age (p=
0.02); that is, older patients (>40 years of age) had more meth-
ylated loci as compared to younger ones (<40 years of age)
(Fig. 2a).
As shown in Fig. 2c, the highest frequency of methylation
was detected for SFRP1 and SFRP2 (73.4 % and 46.9 %,
respectively), followed by SOX17 (20.3 %) and PPP2R2B
(10.9 %) genes. DKK1 and DACH1 were basically
unmethylated (1.6 %). The methylation of individual genes
did not correlate with gender. However, SFRP1 methylation
was found to be significantly more frequent in older patients
as compared to younger ones (p=0.01). Almost all of the
patients (93.75 %) over 60 years of age showed the presence
of SFRP1 promoter methylation, whereas the methylation of
this gene was detected less frequently in younger patient
groups (41–60 years 75.76 %, <40 years 46.67 %) (Fig. 2d).
The results were also analyzed in terms of the correla-
tion with the WHO classification grade of the tumor and
are presented in Fig. 3a. SFRP1 methylation was more
frequent in patients with higher grade tumors (III and
IV). Additionally, SFRP1 methylation showed a significant
negative correlation with patient survival time (Fig. 3b).
All patients with the shortest survival (within 1–3 months
after tumor resection) had SFRP1 promoter methylated,
whereas the frequency of SFRP1 methylation in patients
who survived longer was lower (73 % and 83 % methyl-
ated tumor samples in the “3–12 months” and “12–24
months after tumor resection” groups, respectively). In
the long survival group (>24 months), only 43 % of pa-
tients showed SFRP1 promoter methylation. We also ob-
served a trend towards longer survival accompanied by
lower average MI, calculated for each group of patients
according to their survival time; however, it did not reach
statistical significance.
Table 1 Characteristics of the
studied group of patients A
Type of tumor Number of cases Percentage
Astrocytic tumors 55 85.94 %
Oligodendroglial tumors 1 1.56 %
Oligoastrocytic tumors 2 3.13 %
Ependymal tumors 1 1.56 %
Neuronal and mixed neuronal-glial tumors 3 4.69 %
Unclassified 2 3.13 %
B
WHO tumor grade Number of cases Percentage
I* 4 6.25 %
II** 9 14.06 %
III 23 35.94 %
IV 26 40.63 %
Unclassified 2 3.13 %
*Including one case classified as I/II
**Including one case classified as II/III
C
Gender Number of cases Percentage
Women 28 43.75 %
Men 36 56.25 %
D
Gender Age, range (years) Age, average (years) Age, median (years)
Women 19–77 55 56
Men 16–83 50 56
E
The number of patients with Karnofsky
Performance Status ≥70
48
The number of patients with Karnofsky
Performance Status <70
16
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Discussion
Deregulation of theWnt pathway, as shown in several reports,
is associated with malignant tumor behavior (Fodde and
Brabletz 2007; Delic et al. 2014; Zhang et al. 2012). In glio-
mas, modulation of Wnt signaling has been shown to affect
cell growth andmotility (Lu et al. 2008; Caricasole et al. 2005;
Gong and Huang 2012). Importantly, epigenetic silencing of
genes encoding proteins known to act as antagonists of the
Wnt network was proposed as one of the mechanisms of up-
regulation of the Wnt pathway in malignant gliomas (Foltz
et al. 2010).
In this study, we analyzed the methylation status of six
genes which encode proteins acting asWnt signaling negative
regulators. Beside the genes, which were described earlier as
possible targets of epigenetic silencing in gliomas (SFRP1,
SFRP2, DKK1), the methylation of PPP2R2B, SOX17, and
DACH1 was also assessed. The results showed the methyla-
tion of all the analyzed genes, but to a different extent.
However, the aberrant methylation was observed only in
WHO grade II, III, and IV gliomas; none of the benign grade
I tumors showed methylation of any of the studied genes. The
high prevalence of methylation of the promoter regions of
genes encoding Wnt pathway antagonists in higher grade gli-
omas indicates that this epigenetic mechanism contributes to
the malignant behavior of these CNS tumors. Direct correla-
tion between tumor aggressiveness and promoter methylation
was found for one of the analyzed Wnt pathway inhibitors,
namely SFRP1. Although the MI values did not allow for the
differentiation of advanced tumor grades, the MI of an indi-
vidual patient correlated with his/her age. Older patients had
more methylated loci detected than younger ones. Higher MI
observed in older patients may result from the alterations in
the activity of enzymes involved in epigenetic modifications,
which is a phenomenon typically associated with aging
(Cencioni et al. 2013) or might also be the result of the accu-
mulation of gene methylation changes related to cancer
progression.
Among the individual genes, the most frequentmethylation
was observed in the case of SFRP1. This gene encoding se-
creted Frizzled-related protein 1 was found to be methylated
in almost three quarters of the analyzed glioma samples
(73.4 %), and its methylation correlated significantly with
patients’ age. As mentioned previously, SFRP1 methylation
was found to be related to tumor aggressiveness and, more
importantly, negatively correlated with patients’ survival time.
While hypermethylation of this gene in malignant astrocytic
gliomas has already been described (Götze et al. 2010), the
above-mentioned correlations are novel findings in relation to
glioma and may suggest a potential prognostic value of
Table 2 Primer sequences with
their annealing temperature used
for methylation-specific
polymerase chain reaction (MSP)
analysis
Gene symbol Primer sequence [5′–3′] Primer annealing
temperature (°C)
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SFRP1 methylation in this subtype of cancer. This suggestion
is further supported by recent data on SFRP1mRNA levels in
glioma patients presented in the REMBRANT (Repository of
Molecular Brain Neoplasia Data) and TCGA (The Cancer
Genome Atlas) databases. These data show a significantly
shorter overall survival of glioma patients with low SFRP1
expression comparedwith patients with high SFRP1 transcript
levels (Delic et al. 2014). Our results indirectly indicate that
the hypermethylation of SFRP1 promoter sequence may be
the main mechanism for the decrease in the level of its expres-
sion. Taking into consideration the possible clinical applica-
tion of these findings, reversal of aberrant gene methylation
through the use of epigenome modifying agents opens the
possibility to restore the expression of SFRP1 or other SFRP
family members and, therefore, antagonize deleterious Wnt
signaling (Surana et al. 2014). This possibility has already
been tested in glioma cell lines and was proven to be success-
ful (Schiefer et al. 2014; Surana et al. 2014).
Frequent methylation (55 %) of SFRP2 was also observed,
but its relationship to glioma aggressiveness was not as
straightforward as in the case of SFRP1. The methylation of
SFRP2 did not correlate with either tumor grade or survival
time. Nevertheless, since SFRP1 and SFRP2 proteins are
structurally similar to the extracellular Wnt binding domain
of the Frizzled receptors, they can antagonize Wnt signaling
by sequestering Wnt ligands through the Frizzled cysteine-
rich domain (CRD) or by forming inactive complexes with
the Frizzled receptors (Hendaoui et al. 2012). Thus, it is pos-
sible that the silencing of those two inhibitors is sufficient for
Wnt pathway activation in glioma patients. This might explain
the lower methylation frequency of the other genes analyzed
in our current study. Despite the apparent similar roles of
SFRP1 and SFRP2 proteins, the significance of SFRP2 silenc-
ing in human cancers is generally less clear. It has been report-
ed that, besides acting as a Wnt antagonist, SFRP2 can also
play a role as an enhancer of Wnt/β-catenin signaling (von
Marschall and Fisher 2010).
The SRY-box containing gene 17 (SOX17) was methylated
in around one fifth (20.31 %) of patients. Even though this









































































Fig. 2 The visualization of the
most important results and
representative electropherograms
presenting the method of the
analysis. aMean methylation
index in different age groups with




electropherograms of SFRP1 and
SFRP2 promoter methylation
analysis. For each gene, the upper
part represents the reaction with
primers specific for methylated
sequence, whereas the lower part
represents the reaction with
primers binding to unmethylated
sequence. M completely
methylated human genomic DNA
used as positive control; WBC
white blood cells used as negative
control; Bl blank control; T tumor.
c The frequency of Wnt
antagonists’ promoter
methylation. d The relationship
between promoter methylation of
SFRP1 and patients’ age
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82 % methylated samples of human hepatocellular carcinoma
(Jia et al. 2010) or 93%, 100%, and 94%methylated samples
of nonpolypoid adenomas, polypoid adenomas, and colorectal
carcinomas, respectively (Voorham et al. 2013)], the relevance
of this epigenetic change can possibly be of great importance,
at least in a subset of glioma patients. The studies performed
on rat and mouse models provided evidence that Sox17 regu-
lates the Wnt/β-catenin signaling pathway in oligodendrocyte
progenitor cells (Chew et al. 2011; Sohn et al. 2006). Sox17
knockdown increased the levels of cyclin D1, Axin2, and
activated β-catenin (Chew et al. 2011). The precise role of
SOX17 in human glioma tumor cells, or specifically
oligodendroglioma tumor cells, has not yet been evaluated.
However, in our study, SOX17 was found methylated in ana-
plastic oligodendroglioma samples, so we speculate that epi-
genetic silencing of this gene may function as a factor up-
regulating the Wnt pathway or deregulating the cell cycle in
these tumors.
As far as PPP2R2B is concerned, recent studies show that
its promoter is methylated in colorectal cancer (Tan et al.
2010), ductal carcinoma in situ, and early invasive breast can-
cer (Muggerud et al. 2010), as well as laryngeal squamous cell
carcinoma (Paluszczak et al. 2014). Here, we report that, also,
roughly one tenth of glioma tumor samples (10.9 %) is char-
acterized by this epigenetic change. We also show that
DACH1 and DKK1 methylation is an infrequent event in gli-
oma. This observation is worth noting, considering the fact
that, to date, no or only few studies have addressed this issue.
Mechanisms other than epigenetic were proposed for DACH1
silencing, e.g., homozygous deletion of the chromosomal re-
gion containing DACH1 gene sequence (13q21) (Watanabe
et al. 2011). Interestingly, the induction of the expression of
DACH1 decreased cell proliferation in a series of glioma cell
lines, whereas loss ofDACH1 increased the number of tumor-
initiating cells through transcriptional activation of bFGF
(Watanabe et al. 2011). In contrast to DACH1, epigenetic
changes were reported to play a role in reducing DKK1 ex-
pression in gliomas. In this regard, Foltz et al. (2010) showed
that, among three Wnt antagonist genes, DKK1, SFRP1, and
WIF-1, onlyDKK1 expression was restored by treatment with
DNA demethylating agent 5-azacytidine in T98 glioblastoma
cells, suggesting the presence of promoter hypermethylation.
However, in contrast to the data presented by other authors
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Fig. 3 The relationship between
the frequency of Wnt antagonists’
methylation with tumor grade and
patients’ overall survival time. a
The relationship between the
frequency of Wnt antagonists’
promoter methylation and tumor
grade according to the World
Health Organization (WHO)
classification. b The relationship
between the frequency of Wnt
antagonists’ promoter
methylation and patients’ overall
survival time
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negligible frequency of DKK1 methylation. One reason for
this discrepancy might be the origin of glioma samples, as
Götze et al. (2010) have found DKK1 hypermethylation in
50 % of secondary but not primary glioblastoma.
The overall results of our current study, together with the
hypermethylation of RUNX3 observed in our earlier investi-
gation, indicate that epigenetic silencing of Wnt antagonists
may constitute a crucial mechanism of abnormal up-
regulation of this signaling pathway which is often observed
in gliomas. Moreover, SFRP1methylation can be regarded as
a potential indicator of glioma patient survival.
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